陈涛.美欧“重磅炸弹”药物面临的危机和应对策略及启示[J].全球科技经济瞭望,2013,28(1):69~76 |
美欧“重磅炸弹”药物面临的危机和应对策略及启示 |
The Crisis of Blockbuster Strategy of Multinational Pharmaceutical Companies and Their Solutions |
投稿时间:2012-12-14 修订日期:2012-12-14 |
DOI:10.3772/j.issn.1009-8623.2013.01.011 |
中文关键词: 跨国制药企业;重磅炸弹药物;仿制药;新医保政策 |
英文关键词: multinational pharmaceutical companies;blockbuster drugs;mimicry medicine;new policy on health insurance |
基金项目: |
|
摘要点击次数: 3115 |
全文下载次数: 2551 |
中文摘要: |
“重磅炸弹”药物策略是跨国制药企业近 30 年来快速发展的重要策略。主要有药物发现及临床前研究策略、临床研究策略、市场营销策略、药物研发链策略等。然而,随着国际政治经济形势的变化和医药技术的发展,“重磅炸弹”药物策略面临前所未有的挑战。通过分析跨国制药企业“重磅炸弹”药物策略的基本特点和当前所面临的“危机”,研究了跨国企业可能采取的应对策略,并对我国制药业的发展提出做好学界、临床机构和产业界结合等 5 点建议,以期走出一条不同于传统跨国制药企业的发展之路。 |
英文摘要: |
Blockbuster strategy, including drug discovery and preclinical study strategy, clinical research strategy, marketing strategy, drug R & D chain strategy, is an important engine for multinational pharmaceutical companies’ dramatic development in last three decades. However, this strategy faces the unprecedented challenge
in the wake of the change of international political and economical situation and with the development of medical and pharmaceutical science and technology. The paper analyses main features of blockbuster strategy and its confronted crisis, and introduces the potential countermeasures that will be taken by multinational
pharmaceutical companies in the face of challenge. In the meantime, the paper gives. Some suggestions for Chinese pharmaceutical industry with a development route different from traditional multinational pharmaceutical companies. |
查看全文
查看/发表评论 下载PDF阅读器 |
关闭 |